Fulcrum Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Fulcrum Therapeutics files an amendment to its definitive proxy statement to include the sample proxy card for the 2025 Annual Meeting of Stockholders.
NASDAQ
Fulcrum Therapeutics will hold its annual stockholders meeting on June 26, 2025, to elect directors, vote on executive compensation, and ratify the appointment of Ernst & Young LLP as its independent accounting firm.
NASDAQ
Fulcrum Therapeutics announces its 2025 annual meeting of stockholders to be held virtually on June 26, 2025, covering director elections, executive compensation, and auditor ratification.
NASDAQ
Fulcrum Therapeutics will hold its annual stockholders meeting virtually on June 17, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.
NASDAQ
Fulcrum Therapeutics will hold its 2024 annual meeting of stockholders virtually on June 17, 2024, to vote on director elections and the ratification of its independent accounting firm.